CTLA4 and melanoma: Immunotherapies against immune checkpoints programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), aimed to awake the immune system that will eliminate the tumor, has proven successful in a subset of melanoma patients.